Novel Quinoline-Based P2–P4 Macrocyclic Derivatives As Pan-Genotypic HCV NS3/4a Protease Inhibitors

[Image: see text] We have previously reported the discovery of our P2–P4 macrocyclic HCV NS3/4a protease inhibitor MK-5172, which in combination with the NS5a inhibitor MK-8742 recently received a breakthrough therapy designation from the US FDA for treatment of chronic HCV infection. Our goal for t...

पूर्ण विवरण

में बचाया:
ग्रंथसूची विवरण
मुख्य लेखकों: Shah, Unmesh, Jayne, Charles, Chackalamannil, Samuel, Velázquez, Francisco, Guo, Zhuyan, Buevich, Alexei, Howe, John A., Chase, Robert, Soriano, Aileen, Agrawal, Sony, Rudd, Michael T., McCauley, John A., Liverton, Nigel J., Romano, Joseph, Bush, Kimberly, Coleman, Paul J., Grisé-Bard, Christiane, Brochu, Marie-Christine, Charron, Sylvie, Aulakh, Virender, Bachand, Benoit, Beaulieu, Patrick, Zaghdane, Helmi, Bhat, Sathesh, Han, Yongxin, Vacca, Joseph P., Davies, Ian W., Weber, Ann E., Venkatraman, Srikanth
स्वरूप: Artigo
भाषा:Inglês
प्रकाशित: American Chemical Society 2014
ऑनलाइन पहुंच:https://ncbi.nlm.nih.gov/pmc/articles/PMC4027630/
https://ncbi.nlm.nih.gov/pubmed/24900818
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1021/ml400466p
टैग : टैग जोड़ें
कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!

समान संसाधन